Semaglutide vs dulaglutide
Last updated: October 27, 2026 · 6 min read · By the Grey Peptides Editorial Board
- Semaglutide and dulaglutide are both once-weekly GLP-1 receptor agonists for type 2 diabetes. In their only head-to-head trial, SUSTAIN 7, semaglutide lowered blood sugar and weight more at both dose pairs tested 4.
- Both have outcome trials: dulaglutide reduced a composite of cardiovascular death, heart attack and stroke in REWIND 7, and semaglutide has shown cardiovascular benefit in SELECT and kidney benefit in FLOW 9 10, in different populations.
- Only semaglutide is also approved for weight management, at higher doses as Wegovy 6. As of October 27, 2026, dulaglutide (Trulicity) is approved for type 2 diabetes in adults and children 10 and older and for cardiovascular risk reduction 8.
Side by side
Semaglutide High and dulaglutide High copy GLP-1, the gut hormone that raises insulin after meals, slows the stomach and reduces appetite. Both are injected once a week. They are built differently: semaglutide is a modified GLP-1 peptide with a half-life of about a week 1, while dulaglutide is a GLP-1 analogue linked to part of a human antibody, an IgG4 Fc fragment 2, with a half-life of about five days 3. The table is read from our encyclopedia entries.
| Field | Semaglutide | Dulaglutide |
|---|---|---|
| Encyclopedia entry | Semaglutide Full entry | Dulaglutide Full entry |
| Molecule class | Peptide | Protein, not a peptide |
| Category | Metabolic | Metabolic |
| FDA status | FDA Approved | FDA Approved |
| Approved elsewhere | None recorded | None recorded |
| Evidence grade | High | High |
| Half-life | ≈ 7 days | ≈ 5 days |
| Formula | C187H291N45O59 | Not stated |
| Molecular weight | 4,113.6 g/mol | Not stated |
| WADA 2026 | Not on the 2026 List | Not on the 2026 List |
| WADA 2027 | Not on the 2027 List | Not on the 2027 List |
| In one line | A once-weekly GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management. | A once-weekly GLP-1 receptor agonist built on an antibody fragment (Trulicity), approved since 2014 for type 2 diabetes in adults and children 10 and older. In REWIND it cut major cardiovascular events by 12%; semaglutide beat it head to head. |
| Mechanism | Agonist at the GLP-1 receptor. Enhances glucose-dependent insulin secretion, suppresses inappropriate glucagon, slows gastric emptying, and acts centrally to reduce appetite via hypothalamic and area postrema pathways. Weight loss is driven primarily by the central appetite-suppressing effect rather than the peripheral metabolic actions. | GLP-1 receptor agonism: glucose-dependent insulin release through beta-cell cAMP, lower glucagon and slower gastric emptying (label). DPP-4-resistant changes and the IgG4-Fc fusion give a half-life of about 5 days. Weight loss is modest; semaglutide lowered weight and HbA1c more in the SUSTAIN 7 head-to-head trial. |
| Sources in the entry | 18 | 18 |
| Study cards | 10 | 16 |
| Dosage page | Dosage page | None |
SUSTAIN 7: the direct comparison
SUSTAIN 7 randomised 1,201 adults with type 2 diabetes on metformin, at 194 sites in 16 countries, to one of four weekly treatments for 40 weeks: semaglutide 0.5 mg, dulaglutide 0.75 mg, semaglutide 1.0 mg or dulaglutide 1.5 mg. It paired the low doses and the high doses 4.
At the low doses, HbA1c fell by 1.5 percentage points on semaglutide against 1.1 on dulaglutide; at the high doses, by 1.8 against 1.4. The differences, about 0.4 points, were statistically significant at both levels. Weight fell by 4.6 kg against 2.3 kg at the low doses and by 6.5 kg against 3.0 kg at the high doses 4. Gastrointestinal disorders were the most common side effects for both drugs and the most common reason for stopping: they affected 43% and 44% on the two semaglutide doses, 33% on dulaglutide 0.75 mg and 48% on dulaglutide 1.5 mg 4. The trial was open label and paid for by Novo Nordisk, which makes semaglutide.
The doses have moved on since
Both drugs now go higher than SUSTAIN 7 tested. Dulaglutide's AWARD-11 trial compared 3.0 mg and 4.5 mg with 1.5 mg in adults on metformin; at 36 weeks the 4.5 mg dose lowered HbA1c by 1.77 points against 1.54 and weight by 4.6 kg against 3.0 kg, with more nausea at the higher doses 5. Dulaglutide's label now goes up to 4.5 mg 3; semaglutide's diabetes doses reach 2 mg 1, and its weight-management label has a 2.4 mg maintenance dose with an increase to 7.2 mg allowed 6. No trial has compared the two drugs at those top doses, so the SUSTAIN 7 gap is the best direct evidence there is, and it was measured at doses lower than many people now take.
Heart and kidney outcomes
Both drugs have large outcome trials, but in different people, so they cannot be ranked against each other from these results. REWIND followed 9,901 people with type 2 diabetes for a median of 5.4 years: cardiovascular death, heart attack or stroke occurred in 12.0% on dulaglutide 1.5 mg against 13.4% on placebo, a hazard ratio of 0.88 7. REWIND enrolled people with either a previous cardiovascular event or cardiovascular risk factors 7, and dulaglutide's label covers cardiovascular risk reduction in adults with type 2 diabetes and established disease or multiple risk factors 8.
For semaglutide, SELECT tested the 2.4 mg weight-management dose in 17,604 adults with established cardiovascular disease and overweight or obesity but no diabetes, and found a 20% reduction in major cardiovascular events over a mean 39.8 months of follow-up 9. FLOW tested semaglutide 1.0 mg in people with type 2 diabetes and chronic kidney disease and reduced a composite of kidney failure and related outcomes by 24%; it stopped early for efficacy 10.
Weight, children and who each is for
The clearest practical difference is weight. Semaglutide is approved at higher doses as Wegovy for weight management, and in STEP 1 the 2.4 mg dose lowered weight by 14.9% at 68 weeks against 2.4% on placebo in adults without diabetes 11. Dulaglutide's approval is for type 2 diabetes, in adults and in children 10 years and older, and for reducing cardiovascular events in adults with type 2 diabetes and heart disease or risk factors 8 3. In AWARD-PEDS, in people aged 10 to under 18 over 26 weeks, HbA1c rose 0.6 points on placebo and fell 0.6 and 0.9 points on dulaglutide 0.75 and 1.5 mg 12.
Semaglutide also comes as a daily tablet, Rybelsus, approved in 2019 13; dulaglutide is injection only 3.
How the differences add up (as of October 27, 2026)
Head to head, at the doses tested, semaglutide lowered blood sugar and weight more than dulaglutide with a similar rate of gastrointestinal side effects at the higher doses. Both have outcome-trial evidence: dulaglutide for cardiovascular events in a broad diabetes population, semaglutide for cardiovascular events in people with obesity and for kidney outcomes in diabetic kidney disease. Semaglutide carries a weight-management approval and an oral form; dulaglutide adds an approval for type 2 diabetes in children from age 10. Both are prescription drugs approved in the US. Which suits a given person is a decision for their prescriber, and doses on this page are those studied in trials, not recommendations.
Frequently asked questions
Is Ozempic better than Trulicity?
In SUSTAIN 7, the only head-to-head trial, semaglutide (Ozempic) lowered HbA1c by 1.8 points against 1.4 and weight by 6.5 kg against 3.0 kg at the higher doses tested, over 40 weeks. Newer, higher doses of both drugs have not been compared directly.
Does dulaglutide cause weight loss?
Yes, though less than semaglutide in SUSTAIN 7. In AWARD-11, dulaglutide 4.5 mg lowered weight by 4.6 kg at 36 weeks against 3.0 kg on 1.5 mg. It is approved for type 2 diabetes, not for weight management.
Do both protect the heart?
Both have positive outcome trials in different populations: dulaglutide in REWIND (cardiovascular events 12.0% against 13.4%) and semaglutide in SELECT (20% fewer major cardiovascular events in people with obesity and heart disease).
Related on Grey Peptides
Sources
- Novo Nordisk. OZEMPIC (semaglutide) injection US prescribing information, sections 2 and 12.3: doses up to 2 mg weekly; elimination half-life of approximately 1 week (DailyMed set adec4fd2, version 20, effective June 1, 2026); read October 27, 2026.
- Sanford, M. (2014). Dulaglutide: first global approval. Drugs, 74(17), 2097-103. PMID: 25367716
- Eli Lilly. TRULICITY (dulaglutide) injection US prescribing information, sections 1, 2 and 12.3: doses 0.75 mg up to 4.5 mg weekly; elimination half-life approximately 5 days (DailyMed set 463050bd, version 62, effective June 16, 2026); read October 27, 2026.
- Pratley, R. E., et al. (2018). Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol, 6(4), 275-286. PMID: 29397376
- Frias, J. P., et al. (2021). Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11). Diabetes Care, 44(3), 765-773. PMID: 33397768
- Novo Nordisk. WEGOVY (semaglutide) US prescribing information, section 2: maintenance 1.7 or 2.4 mg weekly, increase to 7.2 mg allowed after at least 4 weeks on 2.4 mg (DailyMed set ee06186f, version 19, effective June 18, 2026); read October 27, 2026.
- Gerstein, H. C., et al. (2019). Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet, 394(10193), 121-130. PMID: 31189511
- Grey Peptides dataset, dulaglutide record: Trulicity (BLA 125469, approved September 18, 2014) and its current label's indications (published August 10, 2026); read October 27, 2026.
- Lincoff, A. M., et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med, 389(24), 2221-2232. PMID: 37952131
- Perkovic, V., et al. (2024). Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med, 391(2), 109-121. PMID: 38785209
- Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med, 384(11), 989-1002. PMID: 33567185
- Arslanian, S. A., et al. (2022). Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes. N Engl J Med, 387(5), 433-443. PMID: 35658022
- Grey Peptides dataset records for both compounds (approvals: Rybelsus 2019; Trulicity BLA 125469, September 18, 2014; studied doses as sourced on each entry); read October 27, 2026.
Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.
New guides and rule changes, by email
One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.
We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead